Lumichrome-d8

Lumichrome-d8 is the deuterium labeled Lumichrome (HY-115385) . Lumichrome, a photodegradation product of Riboflavin, is an endogenous compound in humans. Lumichrome inhibits human lung cancer cell growth and induces apoptosis via a p53-dependent mechanism. Lumichrom is the inhibitor for AKT/β-catenin signaling pathway[1][2].

Product Specifications

UNSPSC

12352005

Target

Akt; Apoptosis; ERK; Isotope-Labeled Compounds; MDM-2/p53; NF-κB; Nuclear Factor of activated T Cells (NFAT) ; p38 MAPK

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Others; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Cancer

Smiles

O=C(N1)C2=NC3=C(C(C([2H])([2H])[2H])=C(C([2H])=C3N=C2NC1=O)C([2H])([2H])[2H])[2H]

Molecular Formula

C12H2D8N4O2

Molecular Weight

250.28

References & Citations

[1]Bergh VJ, et al. Influence of formulation on photoinactivation of bacteria by lumichrome. Pharmazie. 2015;70 (9) :574-580. |[2]Chantarawong W, et al. Lumichrome Inhibits Human Lung Cancer Cell Growth and Induces Apoptosis via a p53-Dependent Mechanism. Nutr Cancer. 2019;71 (8) :1390-1402. |[3]Liu C, et al., Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling. J Cell Physiol. 2018 Nov;233 (11) :8971-8983.